For the abovementioned reasons, STAT3 is considered a therapeutic target in breast cancer, although direct targeting has shown major hurdles in pharmacokinetic profiles, with indirect or combinatorial targeting currently entering clinical testing [44,45,46]. Here, STAT3 is linked to breast cancer.